secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0000950170-25-034169
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics gets Nasdaq extension to regain compliance by June 15, 2025
-------------------------------------------------------------------------

- Panel granted extension; must meet bid price rule by April 25, 2025, all other rules by June 15, 2025.
- Company transferring to Nasdaq Capital Market; previously failed MVLS ($50M), MVPHS ($15M), and bid price ($1) rules.
- Hearing held Feb 13, 2025; Panel accepted Company's compliance plan.
- CEO Hing C. Wong expressed optimism about executing strategy and advancing immunotherapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/0000950170-25-034169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025034169/hcwb-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-034169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer